錦勝集團(控股)(00794.HK)擬2188萬元收購生產設備資產
格隆匯 6 月 24日丨錦勝集團(控股)(00794.HK)發佈公告,2020年6月24日,買方(公司間接全資附屬錦勝包裝(深圳)有限公司)與賣方(東莞市瑞興紙製品有限公司,為獨立第三方)訂立買賣協議,以按總代價人民幣2188萬元購買該等資產。
將收購的資產合共2276個項目,包括用於生產瓦楞紙板及紙製包裝產品的生產機器、辦公室設備、電腦設備及消耗品等。
將根據買賣協議收購的該等資產主要用於確保運作順暢及提高產能。由於現時就集團業務營運使用的若干資產及機器已使用超過20年,董事認為收購該等資產(有關資產較新,亦為更升級版本)將可確保生產順暢並提升整體運作效率,因此長遠將對集團有利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.